Nyxoah to Participate in Jefferies London Healthcare Conference
Nyxoah SA, a medical technology company focused on innovative solutions for Obstructive Sleep Apnea (OSA), has announced its participation in the upcoming Jefferies London Healthcare Conference. The conference will take place from November 14 to 16, 2023, in London.
Corporate Update and Webcast
Olivier Taelman, Nyxoah's Chief Executive Officer, will deliver a corporate update on November 15, 2023, at 5:00pm GMT. The presentation will be available via webcast on Nyxoah's Investor Relations website. The company will also be available for one-on-one meetings with institutional investors attending the event.
Nyxoah is dedicated to developing and commercializing innovative solutions for the treatment of Obstructive Sleep Apnea (OSA). Their lead solution, the Genio® system, is a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy for OSA. Nyxoah aims to provide OSA patients with restful nights and improved quality of life.
The Genio® system received its European CE Mark in 2019 and has expanded its therapeutic indications to include Complete Concentric Collapse (CCC) patients. Nyxoah is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.
For more information about Nyxoah and its innovative solutions, please visit their website at http://www.nyxoah.com/.
Please note that the Genio® system is CE marked since 2019 and is an investigational device in the United States, limited to investigational use only.
For further inquiries, please contact Nyxoah's Chief Strategy Officer, David DeMartino, at email@example.com or +1 310 310 1313.
Implications for Emerging Businesses
Nyxoah SA's participation in the Jefferies London Healthcare Conference could have significant implications for new businesses in the medical technology industry. The company, which specializes in innovative solutions for Obstructive Sleep Apnea (OSA), will be sharing a corporate update at the conference, providing valuable insights for startups and emerging companies in the field.
Learning from Industry Leaders
Nyxoah's lead solution, the Genio® system, is a groundbreaking, patient-centered therapy for OSA. This battery-free hypoglossal neurostimulation therapy has already received its European CE Mark and is currently undergoing the DREAM IDE pivotal study for FDA and U.S. commercialization approval. New businesses can learn from Nyxoah's journey, understanding the steps and strategies involved in developing and commercializing innovative medical solutions.
Furthermore, Nyxoah's presence at the conference opens up opportunities for one-on-one meetings with institutional investors. For new businesses, this highlights the importance of such events for networking and potential investment opportunities. It also underscores the role of effective communication and transparency in attracting investor interest.
In conclusion, Nyxoah's participation in the Jefferies London Healthcare Conference serves as both a learning opportunity and a potential networking platform for new businesses in the medical technology industry.